Kornimate/medical-research-clean huggingface dataset:
identification of new biological markers for the progression of mycobacterium abscessus-induced lung disease in cystic fibrosis

Conditions: Non-Tuberculous Mycobacterial Pneumonia; Cystic Fibrosis Lung

Summary: in this project the investigators aim to identify new biological markers by characterizing the response/inflammation associated with the development and progression of m. abscessus lung disease in patients suffering from cystic fibrosis with the aim of increasing current knowledge available on the development and progression of lung disease.

main objective: evaluate the correlation between early alterations in the profile of specific cell populations or expression markers or soluble immunity activation proteins, considering in particular the development and progression of m. abscessus lung disease in patients with cystic fibrosis. secondary objectives * identify cellular expression profiles associated with the development and progression of m. abscessus lung disease in cystic fibrosis patients and evaluate its ability to predict clinical outcome * identify biomarkers or molecular profiles associated with the development and progression of m. abscessus lung disease in cystic fibrosis patients and evaluate its ability to predict clinical outcome * expand pathogenetic knowledge to support disease progression pulmonary disease from m. abscessus in patients with cystic fibrosis and evaluate their ability to predict clinical outcome. * describe the reciprocal interactions between cellular and humoral components of the response inflammatory disease during m. abscessus infection with/without m. abscessus lung disease.

Eligibility criteria:
inclusion criteria: * patients with a certain diagnosis of cystic fibrosis and visited during normal clinical practice, in accordance with the standard operating procedures in force at the centres. * both sexes * age \>18 years * obtaining informed consent for patients (based on the procedures established by the protocol). exclusion criteria: * patients unable to understand the instructions and information provided and be able to adequately accept the study methods.

Keywords: scrnasec
comparison of liraglutide inhaled into the lungs compared to liraglutide injected under the skin in healthy male volunteers

Conditions: Diabetes; Healthy

Summary: this trial is conducted in europe. the aim of this trial is to determine the relative bioavailability of nnc 90-1170 (liraglutide) when inhaled compared to nnc 90-1170 when injected under the skin.


Eligibility criteria:
inclusion criteria: * no clinically important abnormal physical findings * no clinically relevant abnormalities in the results of laboratory screening evaluation * normal (or abnormal but not clinically significant) ecg (electrocardiogram) * normal (or abnormal but not clinically significant) blood pressure and heart rate * body mass index (bmi) between 20-30 kg/m\^2 or outwith range but not clinically significant * non-smoker * forced vital capacity (fvc) and forced expiratory volume in 1 second (fev1) at least 85% of predicted normal for age, gender and height * fvc ratio at least 75% of predicted normal for age, gender and height exclusion criteria: * a clinically significant illness or infection requiring treatment within the last two months * any infection involving the respiratory system or adverse event that may, in the opinion of the principal investigator, interfere with blood glucose homeostasis * subjects with first and/or second degree relative(s) with diabetes mellitus * donation or loss of greater than 500 ml of blood in the period 0-12 weeks before trial entry * alcohol use in excess of 28 units of alcohol per week. a unit of alcohol is equivalent to half a pint of average strength beer, a glass (125 ml) of wine or a pub measure (25 ml) of spirits, sherry or port * current addiction to alcohol or substances of abuse * females * presence of hepatitis b surface antigen, hepatitis c antibody or hiv (human immunodeficiency virus) 1 or 2 antibodies
effect of esomeprazole 40 mg.daily for 7 days on acid reflux and related arousals during sleep in patients with gerd

Conditions: Gastroesophageal Reflux Disease

Summary: the purpose of this study is to determine if esomeprazole 40 mg. once daily improves not only nighttime symptoms but also significantly reduces conscious awakenings associated with gastroesophageal reflux and consequently improves sleep quality.

twenty gerd patients with nighttime heartburn and/or regurgitation at least 3 times a week will be invited to participate in the study. all patients will undergo upper endoscopy to determine presence or absence of esophageal inflammation(using los angeles criteria). all patients will be evaluated by the demographic,berlin,epworth sleepiness scale questionnaires, and gerd symptom checklist. thereafter,patients will undergo ph testing w/ an actigraph.the morning of ph probe removal,a sleep quality questionaire will be administered. subjects will then receive esomeprazole 40 mg. once daily(30 minutes before breakfast) for 1 week. on day 7,subjects will again undergo ph testing w/ actigraphy, and the results will be analyzed again w/ new integrative software. on the morning of ph probe removal, the sleep quality questionnaire will be re-administered.

Eligibility criteria:
inclusion criteria: * nocturnal symptoms at least twice a week. * ages 18-80 * erosive esophagitis and/or abnormal ph test - * able to read, understand, and complete study questionnaires exclusion criteria: * subjects with barrett's esophagus or peptic stricture on endoscopy * subjects with normal endoscopy and ph test * subjects with previous upper gastrointestinal surgery

Keywords: acid re-flux,gerd sleep related arousals due to gerd treatment of acid reflux during sleep in patients with gerd.
study of segmental renal artery clamping during laparoscopic partial nephrectomy

Conditions: Kidney Neoplasms; Renal Cell Carcinoma

Summary: the purpose of this study is to compare the efficacy and safety of the segmental artery clamping and main renal artery clamping during laparoscopic partial nephrectomy

renal tumor patients,for whom laparoscopic partial nephrectomy is suitable, will be randomly divided into two groups,segmental artery clamping group and main artery clamping group. all procedures were performed by the same laparoscopic surgeon. blood loss, operation time, warm ischemia time, complications and affected renal function before and after operation will be recorded and compared. the safety and efficiency of laparoscopic partial nephrectomy with segmental renal artery clamping will be evaluated in comparison with the conventional main renal artery clamping technique.

Eligibility criteria:
inclusion criteria: * 20\<age\<70yr * stage t1a * patients volunteered for this study and provided written informed consent exclusion criteria: * bilateral renal tumor * tumor of solitary kidney * glomerulonephritis * renal insufficiency * gfr of invalid kidney less than 30ml/min * presence of suspect metastasis * serious systematic disease: severe coagulation disorders * important organ insufficiency and severe psychological disease

Keywords: renal tumour partial nephrectomy laparoscope segmental renal artery clamping
prediction of intraoperative blood loss and postoperative recovery by liver stiffness measurement (fibroscan®) in right hepatectomy

Conditions: Liver Malignancy

Summary: liver stiffness measurement (lsm) using fibroscan®(echosens, paris, france) is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (ls). although recent advances in surgical techniques and perioperative management have made with established perioperative management have now made it possible to perform hepatectomies as a safe procedure with minimum mortality, the possibility of massive blood loss and resultant transfusion during hepatectomy still exist. the objective of this research was to identify the role of liver stiffness measurement for the prediction of intraoperative blood loss and postoperative recovery after elective right hepatectomy.


Eligibility criteria:
inclusion criteria: * patients undergoing right hepatectomy between august 2007 and july 2011 exclusion criteria: * patients undergoing right hepatectomy without preoperative liver stiffness measurement
ovarian hyperstimulation syndrome prevention

Conditions: Ovarian Hyper Stimulation Syndrome (OHSS)

Summary: ovarian hyperstimulation is a very hazardous complication of icsi

ovarian hyperstimulation could be mild , moderate , severe or marked

Eligibility criteria:
inclusion criteria: * women with pcos coming for icsi exclusion criteria: * women who donnot have pcos

Keywords: ohss mild moderate severe
comparative trial to investigate the dose-response of 4 different dose levels of minirin melt and placebo

Conditions: Nocturia

Summary: this is a multi-centre, randomised, placebo-controlled, double-blind, parallel-group comparative trial to be conducted in nocturia patients. the trial is designed to characterize the dose-response relationship of minirin (desmopressin) melt in order to establish correct dose recommendations in the target patient population. in particular, the trial is designed to link the duration of action to the clinical endpoint. furthermore, the trial is designed to describe the safety of four different dose levels of desmopressin.


Eligibility criteria:
inclusion criteria: * given written informed consent prior to any trial-related activity is performed * aged 55-75 years * mean number of nocturnal voids of at least two per night * reached post-menopause (applicable to females only) exclusion criteria: * evidence of bladder outlet obstruction (boo); or a urine flow of less than 5 ml/s (applicable to males only) * a surgical treatment for boo or prostatic hyperplasia within the past 6 months (applicable to males only) * showing symptoms of any of the following diseases and having a mean number of nocturnal voids exceeding four per night: benign prostatic hyperplasia, overactive bladder, interstitial cystitis, severe stress urinary incontinence * psychosomatic or habitual polydipsia * urinary retention; or a post void residual volume in excess of 150 ml * a history or complication of urologic malignancy (e.g. bladder cancer or prostate cancer) * complication of genito-urinary pathology (e.g. infection, stone, or neoplasia) * complication of neurogenic detrusor activity * complication or suspicion of heart failure * uncontrolled hypertension * uncontrolled diabetes mellitus * complication of hepatobiliary disease * abnormal serum creatinine level * complication of hyponatraemia, or serum sodium level \<135 meq/l * central or nephrogenic diabetes insipidus (cdi or ndi) * syndrome of inappropriate antidiuretic hormone (siadh) * obstructive sleep apnea * alcohol dependency or drug abuse * a job or lifestyle that may interfere with regular night-time sleep * previous desmopressin treatment * treatment with another investigational product within the past 3 months * a need for treatment with a prohibited concomitant drug for a complication or other problem * a mental condition, the lack of decision-making ability, dementia or a speech handicap * any other reason that the investigator believes inappropriate

Keywords: nocturia bladder function
national cancer institute thai cancer anemia survey

Conditions: Anemia; Cancer

Summary: the purpose of this study is to create a large thailand database documenting the severity of anemia and its management in the cancer population.

thai cancer anemia study (tcas) is a prospective survey that will track anemia management in an adult cancer population. this survey is not intended to interfere with standard medical practices for handling anemia. information on laboratory values including target and achieved hemaglobin (hb) levels during chemotherapy cycles, use of blood transfusions, iron supplementation, and epoetin will be collected in addition to information on cancer status and treatment. data on the level that triggers clinicians to decide on the need for anemia therapy will also be collected. each patient included in the survey will be followed for six months. observational study - no investigational drug administered

Eligibility criteria:
inclusion criteria: * patients with cancer exclusion criteria: * n/a

Keywords: cancer anemia survey thai national cancer institute
detecting circulating emboli in patients with acute venous thromboembolism

Conditions: Venous Thromboembolism

Summary: the purpose of this study is to further evaluate and adjust the photoacoustic flow cytometry device and its use in detecting circulating emboli. study design: cohort 1: normal healthy volunteers will be enrolled to further adjust the device settings. cohort 2: use the phatoacoustic flow cytometry (pafc) to detect circulating emboli in vivo in patients with venous thromboembolism at diagnosis, during and after anticoagulation therapy.

laser beam from the investigational device phatoacoustic flow cytometry pafc will be applied to skin and underlying blood vessels. the optical and ultrasound signal will be collected for analysis. on each tested vessel, we will estimate the vessels diameter (using optical or/and ultrasound imaging). the subject's skin pigmentation will be classified as light, medium, or dark. a photoacoustic (pa) contrast will be considered usable for detection of circulating emboli if the photoacoustic signal from the vessels is more than 1.3-fold higher than the photoacoustic signal from surrounding tissue. the device for subjects enrolled on cohort 2 will be completed on day 0 (immediately after venous thromboembolism diagnosis and prior to anticoagulation therapy), day 7 ± 3 days after initiation of anticoagulation therapy, one week ± 3 days after completion of planned anticoagulation therapy and one month ± 3 days after completion of planned anticoagulation therapy. anticoagulation therapy is part of the patient's normal standard of care and is not part of this study however data from what therapy was received may be captured. d-dimer test will be performed on each time point as part of their normal standard of care however if the d-dimer test is not ordered as part of the standard of care it will be required for the study.. patients will then be followed in hematology clinic to monitor the venous thromboembolism recurrence every 3 months for one year.

Eligibility criteria:
inclusion criteria cohort 1: * age 18 years and older * willing to adhere to protocol. * signed informed consent exclusion criteria cohort 1: * unable to provide informed consent. * history of venous thromboembolism. * currently receiving anticoagulant therapy. inclusion criteria cohort 2: * ages 18 years and older * confirmed new diagnosis of acute venous thromboembolism. * performance status of equal to or less than 2. * able to receive anticoagulation therapy. * willing to adhere to specific protocol requirements. * signed informed consent. exclusion criteria cohort 2: * life threatening venous thromboembolism.
sphenopalatine block vs dexmedetomidine infusion in trans nasal endoscopic pituitary surgery

Conditions: Sphenopalatine Ganglion Nerve Block; Transnasal Endoscopic Pitutary Surgery

Summary: improving pain and surgical field by using sphenopalatine ganglion block and dexmedetomidine in trans-nasal endoscopic pituitary surgery.

pituitary neoplasm is one of the most common sellar pathology. trans-nasal endoscopic pituitary surgery (teps) evolved rapidly, almost replacing the craniotomy approach. teps, a surgical instrument, is primarily executed through a minimally invasive approach through the nostril to access a pituitary tumor. that is why the anesthetic plan must ensure the best possible surgical field visualization and the most adequate analgesia. multimodal anesthesia including regional and general anesthesia are obtained to optimize surgical field by decreasing bleeding, reduce pain, promote rapid recovery and potential economic gains for the hospital. the sphenopalatine ganglion block (spgb) is considered one of the regional anesthetic techniques that is safe and easy anesthetic procedure used to control bleeding and for postoperative analgesia. dexmedetomidine (dex) has become popular for induced hypotension. it is an α2-adrenoceptor agonist with a sympatholytic and analgesic effect. it provides a unique conscious sedation without respiratory depression. it is used effectively in optimizing surgical field through its hemodynamic stability effect.

Eligibility criteria:
inclusion criteria: * age: between 21-64 years old. * sex: males and females. * body mass index: 35 kg/m2. * asa physical status: grade ⅰ-ⅱ. exclusion criteria: * patients receiving beta blockers, anti-coagulants and antihypertensive medications also patients receiving clonidine or benzodiazepines, neuroleptics or antidepressants two weeks prior to the study. * any contraindication for regional anesthesia e.g. coagulopathy, infection at site of block and hypersensitivity to any drug used in this study. * patients who are known to be drug addict.
povidone-iodine vs essential oil vs tap water gargling for covid-19 patients

Conditions: COVID-19

Summary: the purpose of this study is to assess the ability of regular gargling to eliminate severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in the throat and nasopharynx. this 4 arms interventional study compares the effect of gargling using povidone-iodine, essential oils- based, tap water with control (no intervention) among stage 1 coronavirus disease-2019 (covid-19) patients. findings from this study will provide new insight into the importance of gargling in the treatment and prevention of covid-19.

experimental plan after consent is taken, all groups will be briefed regarding the study protocol separately. * group a will be briefed on the correct procedures of gargling with betadine®. the participants will be instructed to take 10ml of povidone-iodine (pvp-i), tilt their heads backward and gargle for 30 seconds, three times per day for 7 days * group b will be briefed on the correct technique of gargling with listerine®. the participants will be instructed to take 20ml of essential oils, tilt their heads backward and gargle for 30 seconds, three times per day for 7 days * group c will be briefed on the correct technique of gargling with hydrogen peroxide. the participants will be instructed to take 10ml of hydrogen peroxide, tilt their heads backward and gargle for 30 seconds, three times per day for 7 days * group d will be briefed about the involvement in this study. they will be managed according to the standard protocol of the hospital with no additional intervention. monitoring 1. oropharyngeal and nasopharyngeal swabs will be taken on day 4, 6 of intervention, and day 12 post-intervention. the swabs will be subjected to detection of sars-cov-2 by real-time reverse transcriptase-polymerase chain reaction (rt rt-pcr). 2. patients will be given a chart for them to record their gargling practice and symptoms (if any) during the intervention period ( 7 days) 3. clinical data collection sheet will be provided to attending clinicians. the required information includes demographic data, daily vital signs, serial absolute lymphocytic count, ldh, chest radiograph, and symptoms. clinical monitoring will be done until day 14 of the intervention.

Eligibility criteria:
inclusion criteria: 1. adult aged 18 years and above 2. able to understand instructions 3. stage 1 covid-19 4. \< 5 days of illness or diagnosis exclusion criteria: 1. less than 18 years old 2. unable to understand instructions 3. stage 2 \& 3 covid-19 4. respiratory symptoms or fever on admission 5. abnormal chest radiograph or computed tomography (ct) findings on admission

Keywords: gargle povidone-iodine essential oils tap water
tablet-based interactive distraction preoperative anxiety in children: a randomized controlled trial

Conditions: Children Under General Anaesthesia

Summary: children develop anxiety during the induction of anaesthesia and video-games might reduce or alleviate it. the investigators intend to conduct a clinical trial to study the effect of tablet-based interctive games on alleviating preoperative anxiety.

it is estimated that 50% of children may suffer preoperative anxiety. they have a higher risk of generating postanesthetic delirium and behavioral changes in the postoperative period up to 67% of cases. for the management of preoperative anxiety there are pharmacological and non-pharmacological treatments. within the first group there's the use of benzodiazepines of short half life like midazolam, however, the use of this medication is not exempt of risks such as paradox reactions, respiratory depression, among others. this is why the non pharmacological mesures have taken force and every day there is more evidence regarding its effectiveness. there are no reports in chile or latin america regarding the use of this tools, this is why the investigators designed this study to prove the effectiveness of audiovisual distraction measures in reducing preparatory anxiety compared to premeditation with midazolam.

Eligibility criteria:
inclusion criteria: children aged 2-10 years, under major surgery ambulatory program at hospital carlos van buren, with no contraindication for the use of midazolam. exclusion criteria: patients with cognitive impairment or sensory deficit patients with previous history of major surgery will also be excluded patients with myastenia "hard airway" history of paroxystic reaction to benzodiazepines attentional deficit hyperactivity disorder sleep aphnea full stomach adenotonsillar hypertrophy respiratory acute infections
multi-omics to predict responses to biologics in ibd

Conditions: Crohn Disease; Ulcerative Colitis

Summary: inflammatory bowel disease (ibd) is a chronic immune-related disease, which mainly affects the digestive tract. there are mainly two forms of the disease, including crohn's disease (cd) and ulcerative colitis (uc). biologics have revolutionized the treatment of inflammatory bowel disease with good efficacy and safety. however, 20-50% of patients may not response to or lose response to biologics. unfortunately, there has been no factors or measures that may predict the efficacy or safety of biologics. in this study, a large prospective cohort study is conducted to evaluate the efficacy and safety of biologics (infliximab, adalimumab, vedolizumab, ustekinumab, and other approved biologics) in patients with inflammatory bowel disease in the real clinical practice. meanwhile, a multi-omics approach involving transcriptomics, microbiome, proteomics, and metabolome, are adopted to explore biomarkers or factors that predict the therapeutic efficacy or safety of biologics. the mechanism underlie the disease will also be explored.


Eligibility criteria:
inclusion criteria: 1. for patients with ibd: * patients with ibd treated with approved biologics * age 18 or over * written informed consent obtained from patient for participation 2. for non-ibd healthy volunteers: * patients without the diagnosis of ibd or other conditions that, in the opinion of the investigator, not suitable to participate in the study * age 18 or over * written informed consent obtained from patient for participation exclusion criteria: * unable to obtain written informed consent * patient is, in the opinion of the investigator, not suitable to participate in the study